{
  "report_rows": [
    {
      "kpi": "Q2 2026 Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$2.87B vs. cons ~$2.815B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Non-GAAP EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.62 vs. cons ~$2.49",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 da Vinci Procedure Growth (YoY)",
      "prediction": "BEAT",
      "answer": "pred ~15.0% vs. cons ~14.0%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 da Vinci Procedure Growth Guidance",
      "prediction": "BETTER",
      "answer": "guide ~14.5%-16.5% vs. cons ~13.5%-15.5% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Non-GAAP Gross Margin Guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~67.5%-68.5% vs. cons ~67.5%-68.5% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Tariff Cost Impact Guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~100bps vs. cons ~100bps (FY2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 5.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 3.2,
  "day5_path": "FADE",
  "day5_rationale": "Beat-and-modest-raise triggers a sharp relief rally off deeply oversold, sentiment-driven levels (stock down >30% from highs), but the raise likely falls short of fully resolving the structural overhangs (China reimbursement clarity pushed to 2027, 2H tariff/input cost inflation still flagged, recall remediation costs still unquantified). As sell-side models roll forward, implicit 2H27 margin and China-growth assumptions get trimmed even after the Q2 beat, causing part of the initial pop to fade over the following days rather than fully follow through.",
  "day5_confidence": "LOW"
}